This led to a similar frequency of cytotoxic effector and effector memory cells, but a lower frequency of triple positive, putatively exhausted PD-1+Tim3+Lag3+ CD8 T-cells (15% in combination vs 35% in CEA-TCB monotherapy) and higher frequency of intra-tumor CXCR3+ CD8+ T-cells (11% in combination vs 5% in CEA-TCB monotherapy) (Figure 5B). Here, CEACAM5 is linked to neoplasm.